CTRI/2019/10/021771已完成未知
Comparison of 1-day vs. 3-day intravenous terlipressin in patients with acute variceal bleeding: open-label randomized control trial. - TER1vs3
Dr Shalimar0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. (compensated or decompensated) with acute variceal bleeding
- •2.Willing to participate in the study
排除标准
- •1.Variceal bleeding secondary to causes other than cirrhosis. eg, extrahepatic venous obstruction, hepatic venous outflow tract obstruction
- •2.Patients with malignancy/disseminated intravascular coagulation (DIC)/known coagulopathic disorder (hemophilia) apart from cirrhosis.
- •3.History of intake of platelets inhibitors (e.g., aspirin, clopidogrel) and drugs affecting coagulation cascade (e.g., vitamin K antagonists) within the past 7 days
- •4.Pregnant women
- •5.Patients with chronic renal failure
- •6.Patients with shock or requiring mechanical ventilation
- •8.Acute on chronic liver failure
- •9.Hepatorenal syndrome
- •10.Hepatic encephalopathy
- •11.Contraindication to endoscopy
- •12.Not willing to provide consent
- •13.Active angina, Recent Myocardial infarction or dynamic EKG changes
- •14.Failure to control variceal bleed on initial endoscopy
- •15.Isolated gastric variceal bleeding
- •16.Spontaneous bacterial peritonitis at presentation
- •17.Hepatocellular carcinoma or other liver metastatic malignancy
研究者
相似试验
尚未招募
不适用
A clinical trial to study the efficiency of two drugs terlipressin and noradrenaline in patients with low blood pressure and liver failure.CTRI/2021/09/036920Pt BD Sharma Pgims rohtak
尚未招募
2 期
Comparison of Terlipressin and low dose Terlipressin and noradrenalin in HRS-AKI patients of ACLFCTRI/2023/10/058546on sponsered
进行中（未招募）
1 期
A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naive Subjects with Genotype 1 Chronic Hepatitis C - ADVANCEEUCTR2007-004720-20-GBVertex Pharmaceuticals Incorporated1,050
进行中（未招募）
1 期
A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naive Subjects with Genotype 1 Chronic Hepatitis CEUCTR2007-004720-20-FRVertex Pharmaceuticals Incorporated1,050
进行中（未招募）
1 期
A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naive Subjects with Genotype 1 Chronic Hepatitis C - ADVANCEChronic Hepatitis C, Genotype 1MedDRA version: 9.1Level: LLTClassification code 10019744Term: Hepatitis CEUCTR2007-004720-20-ATVertex Pharmaceuticals Incorporated1,050